vaginal resilience / hormonal & gut

SKU II · vaginal sovereigntyRebel Flora

Sovereign V — reclaim the seat.

Vaginal sovereignty, in nine deliberately selected species. *L. acidophilus* La-14, *L. rhamnosus* HN001, *L. rhamnosus* Rosell-11 + *L. helveticus* Rosell-52 (Lacidofil®), *B. subtilis* HU58, *L. reuteri* 1E1, *B. coagulans* SC208, *L. gasseri* LG36, *L. salivarius* LS33 — a multi-genus foundation for the vulvovaginal microbiome and the gut microbiome that speaks to it, shipped at the dose the colonisation literature reports. ~25 B CFU per two-capsule serving at manufacture. Structure-function support for a healthy vaginal microbiome, healthy gut microbiome, bowel function, nutrient digestion, and immune function. Sequence-verified every lot, panel-printed, citation on the bar. Your body, your seeding, your evidence.

See the strain list Press & wholesale

vaginal resilience / hormonal & gut

Pharmacist-selectedRebel Flora

Sovereign V

Nine-species multi-genus vaginal-and-gut stack — *L. acidophilus* La-14® · *L. rhamnosus* HN001™ · *L. rhamnosus* Rosell®-11 + *L. helveticus* Rosell®-52 (Lacidofil®) · *B. subtilis* HU58™ · *L. reuteri* 1E1 · *B. coagulans* SC208® · *L. gasseri* LG36 · *L. salivarius* LS33. One of the most-studied probiotic organisms ever deposited in a culture collection, sequenced on every batch and printed on every panel.

CFU dose: 25 B CFU per 2-capsule serving at manufacture (9 × 10⁹ La-14 + 6 × 10⁹ HN001 + 4 × 10⁹ Lacidofil® + 2 × 10⁹ HU58 + 2 × 10⁹ 1E1 + 1 × 10⁹ SC208 + 5 × 10⁸ LG36 + 5 × 10⁸ LS33)
At time of: Manufacture (printed at fill)
Strain ID: La-14® · HN001™ · Rosell®-11 · Rosell®-52 · HU58™ · 1E1 · SC208® · LG36 · LS33

Pharmacist brief

Read like a clinician, not a marketer.

The four blocks below reproduce what the pharmacist writes on the brief — strain designations, citation trail, the narrative rationale, and the lane boundaries Sovereign V is honest about. The vulvovaginal microbiome is a women’s-health surface, and the panel-printed CFUs land at the dose the colonisation literature reports.

Pharmacist rationale

Why this strain, this dose, this panel.

Sovereign V is a nine-species vaginal-and-gut stack, every organism sequenced at its type strain, every dose printed on the panel at the time of manufacture. The vaginal-probiotic literature is built on these strains and these CFU windows, and so is our panel — we did not invent novel species, we selected the ones the human trial record actually anchors to and printed the lot-level sequence on every batch. Vaginal sovereignty starts with knowing what you are seeding.

Counterculture Rx clinical pharmacist · strain brief

Clinical evidence

The primary studies behind this strain.

The dosing window is anchored to the peer-reviewed work below. Every row is identifiable by DOI and resolves to a primary source — no white-paper or QR code behind a marketing wall.

Citation 01Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized controlled trial
FEMS Immunology & Medical MicrobiologyReid G., Charbonneau D., Erb J., Kochanowski B., Beuerman D., Poehner R., Bruce A. W.
2003doi:10.1016/S0928-8244(02)00465-0
Citation 02Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized clinical trial
Microbes and InfectionAnukam K. C., Osazuwa E., Osemene G. I., Ehigiagbe F., Bruce A. W., Reid G.
2006doi:10.1016/j.micinf.2006.01.003
Citation 03Randomized trial of Lactin-V (Lactobacillus crispatus CTV-05) for prevention of bacterial vaginosis
New England Journal of MedicineCohen C. R., Wierzbicki M. R., French A. L., Morris S., Hanson B. M., Overcash J., Smith-McCune K., Wang A. Z., Buckanovich R., Hilton J. F., Murphy M., Thurman A. R., Siegler N., Johnston C., Trujillo S. L., Lipscomb J. M., Swezey J., Anderton P., Hedges S., Tibbitt J., PTN-CW Group
2020doi:10.1056/NEJMoa1915251

Story behind the SKU

Why this stack and these doses

The vaginal-and-gut lane is the most studied probiotic space in the female-health literature, and it is also the most over-marketed. Sovereign V takes the opposite move: nine species, every one sequenced at its type strain, every dose printed on the panel at the time of manufacture. The stack reads L. acidophilus La-14®, L. rhamnosus HN001™, L. rhamnosus Rosell®-11 paired with L. helveticus Rosell®-52 as the Lacidofil® blend, B. subtilis HU58™, L. reuteri 1E1, B. coagulans SC208®, L. gasseri LG36, L. salivarius LS33 — eight organism rows from nine distinct species, printed on the same panel.

The vulvovaginal microbiome is a remarkable ecosystem, and it speaks to the gut microbiome through the gut-vaginal axis the literature is now mapping in detail. Resilience across the menstrual cycle, across hormonal shifts, across the perimenopausal arc — the connection is real, and the standard “eat some yoghurt” advice is a quiet dismissal of what that ecology actually does for the rest of the body. Sovereign V is a deliberate re-seeding of that surface with helpful microbial allies, on the panel-printed dose window the colonisation trials used.

Twenty-five billion CFU per two-capsule serving is the dose window the vaginal-and-gut literature reports — the GR-1 / RC-14 colonization work, the BV metronidazole adjuvant trial, and the L. crispatus CTV-05 prevention RCT all run inside this window. We do not stack the dose higher; no published dose-response analysis shows additional benefit above it for the vaginal-resilience lane, and exceeding it has not been evaluated for tolerability.

Two capsules, once a day, on the panel-printed CFU window — not stacked above it.

What it is for

Sovereign V is the lane-defining SKU for vaginal resilience and the female-health GI axis the panel names on the formula. It is, line by line, the structure-function brief: the formula's normal dietary contribution to a healthy vaginal microbiome, the normal contribution to a healthy gut microbiome, the normal contribution to bowel function, to nutrient digestion and absorption, and to immune function — the same immune function that underpins cycle resilience and gut integrity in the rounds we seldom get to talk about in primary care.

Sovereign V is NOT the right answer for daily GI foundation on its own — CounterStrike is. CounterStrike is the seven-strain yeast-inclusive moderate-dose daily GI layer that holds the whole-body axis; Sovereign V is the multi-species vaginal-and-gut formula printed on its own panel for deliberate re-seeding of the vulvovaginal surface. Sovereign V is NOT the right answer for long-horizon metabolic, insulin, or cycle-shift work — Engine of Change is.

The bar on the panel names exactly what it can and cannot do. We do not make disease claims; the pharmacist will tell you so on purpose.

How we verify each lot

Whole-genome sequencing at all nine species loci (La-14 / HN001 / Rosell-11 / Rosell-52 / HU58 / 1E1 / SC208 / LG36 / LS33) on every batch. Every sequence is checked against the strain-reference panel — drift is a fail.
CFU plate count per organism at the moment of fill, printed on the bottle. The total CFU is the sum of the eight per-organism counts (the Lacidofil® blend is one organism row, two species), not an aggregate.
Acid- and bile-tolerance assays on the seven Lactobacillus strains — they must survive the upper-GI transit the vaginal-administration literature assumes.
Spore-form viability on the two Bacillus strains (HU58, SC208) — they must arrive live and survive at room-temperature storage the way the human-trial formulations did.

Strain-specific bibliographies (per La-14, HN001, Rosell-11, Rosell-52, HU58, 1E1, SC208, LG36, LS33) are layered in by the clinical pharmacist in a follow-up commit. None of these methods are proprietary.

When Sovereign V is the wrong choice

If the goal is daily GI foundation on the panel-published multi-strain+yeast dose window — the everyday gut-matters work that holds cycle resilience in place — CounterStrike is the SKU. If the goal is long-horizon metabolic, insulin, or perimenopausal cycle-shift support, Engine of Change is the SKU. Sovereign V is deliberately a nine-species vaginal-and-gut product for deliberate re-seeding of the vulvovaginal microbiome; it will not substitute for what CounterStrike or Engine of Change do better. The pharmacist will tell you so.

Vaginal resilience · on the brief

Vaginal support, on the record.

Vaginal support, in Sovereign V's lane, is structure-function work — the deliberate re-seeding of the vulvovaginal surface with beneficial microbial allies, on the dose window and the panel the literature reports. The five blocks below walk through what the panel name means in this lane: what vaginal support actually is, what the Lactobacillus-dominant backdrop the literature reports does at the surface, what the literature is mapping at moments of disruption, what changes across the perimenopausal arc, and where the informed-choice line sits. Read it, ask the questions, then decide.

01On the brief

Vaginal support, defined.

Vaginal support, in the probiotic literature Sovereign V sits inside, is the deliberate re-seeding of the vulvovaginal surface with beneficial microbial allies — the species and the dose window the colonisation trials report, on the panel printed at the time of manufacture. Not a treatment for any specific condition. Not a substitute for clinical evaluation. A structure-function posture: a daily, panel-verified dose of helpful bacteria, so the vulvovaginal surface keeps the microbial allies the literature describes.

That posture is what the panel-printed CFU window, the strain sequence, and the lot-level citation ship. Sovereign V does the lane-honest version — nine sequentially-verified species, at the dose window the human trial record reports, printed on the bar.

→ See citations: Reid 2003 · Anukam 2006 · Cohen 2020

02On the brief

Lactobacillus-dominant flora, pH 3.8–4.5.

The vulvovaginal surface, in cohorts of healthy adult humans, is most often dominated by Lactobacillus species — L. crispatus, L. gasseri,L. rhamnosus, L. iners, L. jensenii, by cohort and assay. A Lactobacillus-dominant flora keeps the surface pH in the acidic range — roughly 3.8 to 4.5 — by fermenting the glycogen exfoliated from the vaginal epithelium into lactic acid. That lactic-acid production is the mechanism the literature points to: a low pH is unfavourable to many of the opportunistic organisms the surface sees. Some Lactobacillus strains also produce hydrogen peroxide at the surface, a second mechanism the older colonisation literature describes.

Sovereign V's panel is built around that Lactobacillus-dominant lane. Five of the nine species on the panel are Lactobacillus; the remaining four — paired as the Lacidofil® blend and the two Bacillus rows — round out the multi-genus foundation the bar reads.

→ See citations: Reid 2003 · Anukam 2006 · Cohen 2020

03On the brief

What the literature is mapping.

Yeast overgrowth (vulvovaginal candidiasis), bacterial vaginosis (BV), and recurrent urinary tract infection are the three contexts the women's-health literature is most actively mapping at the microbiome layer. The Reid 2003 L. rhamnosus GR-1 oral trial, the Anukam 2006 metronidazole-adjuvant trial, and the Cohen 2020 L. crispatus CTV-05 trial all sit inside this literature — at the colonisation, the adjuvant, and the prevention edges of where the human trial record stands.

Those are the contexts the literature describes. Sovereign V is not positioned to prevent, diagnose, or treat any of them. It is positioned for the structure-function support its panel names — a healthy vaginal microbiome, supported on the dose window the human trial record reports.

→ See citations: Reid 2003 · Anukam 2006 · Cohen 2020

04On the brief

Perimenopause, menopause, and the estrogen effect.

Across perimenopause and menopause, declining estrogen narrows the vaginal epithelial glycogen layer — the substrate Lactobacillus ferment into lactic acid. As that glycogen substrate thins, the Lactobacillus-dominant flora often thins with it, and the surface pH drifts upward toward the 5–7 range the opportunistic organisms favour. The literature describes that drift as one of the largest microbial shifts an adult woman's body goes through — and the recovery window is real, on a horizon of years rather than days.

Sovereign V does not replace the hormonal conversation; that conversation belongs with a qualified clinician. It sits in the structure-function lane: re-seed the surface with the Lactobacillus allies the panel documents, on the dose window the literature reports, so the panel says exactly what is going in. If you are in this arc and the conversation matters to you, the citation trail is on the bar — read it, ask the questions, then decide.

→ See citations: Reid 2003 · Anukam 2006 · Cohen 2020

05On the brief

Informed choice, on the panel.

The pharmacist's brief is on the panel — what is in Sovereign V, what dose, what every lot is sequenced against. The citation trail resolves to primary, peer-reviewed sources, anonymous on the formula by deliberate pharmacist protocol. Nothing on the label reads as a treatment claim. The Counterculture Rx clinical pharmacist will tell you so on the brief: Sovereign V is a structure-function support tool, not a clinical answer.

If you are experiencing recurrent or concerning symptoms — irritation, unusual discharge, pelvic pain, urinary symptoms that return — see a qualified clinician. Sovereign V is the colony re-seeding tool, not a substitute for clinical evaluation. Rebel Flora. Pharmacist brief. Counterculture Rx.

→ Press & wholesale: counterculture@polsia.app